-
Article
TOXICAN: a guide for grading dermatological adverse events of cancer treatments
The dermatological toxicity of cancer treatments is frequent and sometimes debilitating. Its reference classification, the NCI-CTCAE (National Cancer Institute–Common Terminology Criteria for Adverse Events), ...
-
Article
Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab
Ipilimumab is a monoclonal antibody blocking the inhibitory molecule CTLA4 expressed by activated T lympocytes, used for the treatment of metastatic melanoma. Recent studies have shown its potential efficacy o...
-
Article
Incidence and characteristics of melanoma brain metastases develo** during treatment with vemurafenib
Vemurafenib is indicated for the treatment of patients with BRAF V600 -mutant metastatic melanoma. We studied for the first time the characteristics of brain met...
-
Article
Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm
Cutaneous adverse events induced by epidermal growth factor receptor (EGFR) inhibitors can hamper the patients' quality of life. The aim of our work was to draft an algorithm for the optimised management of th...
-
Article
Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
Advances in the understanding of the mechanisms involved in oncogenesis have led to the development of so-called targeted therapies such as epidermal growth factor receptor (EGFR) inhibitors, which take on an ...
